Entries by admin

Posiphen® Restores Brain Function, Cognition and Memory in Transgenic Alzheimer Mice

Berwyn, PA, October 22, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease(AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound “Posiphen® Recovers Memory, Learning […]

QR Pharma Presents at the University of Pennsylvania: Convergence of Factors Leading to Neurodegenerative Disorders

Berwyn, PA, September 20, 2012: QR Pharma, Inc., a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders presented at the University of Pennsylvania in Rod and Maryellen Eckenhoff’sAnesthesia department. Dr. Maccecchini discussed the most recent developments and […]

QR Pharma announces the start of a phase I clinical study for Bisnorcymserine , First human trial of compound discovered at NIH may treat Alzheimer’s disease

Berwyn, PA, July 24, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that it initiated the first human clinical trial of the company’s compound bisnorcymserine (BNC) to evaluate safety […]

QR Pharma Announces Publication on Posiphen Clinical Trials Showing Promise for Alzheimer’s Patients

Berwyn, PA, July 17, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that a report on the early stage clinical trials of its lead compound Posiphen® appeared online July […]

QR Pharma to Present at the Alzheimer’s Association International Conference

Berwyn, PA, July 10, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting research data on its lead compound Posiphen® at the Alzheimer’s […]

QR Pharma to Present at 11th Annual World Pharma Congress

Berwyn, PA, May 29, 2012: QR Pharma, Inc. (QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, QR’s chief executive officer, will speak at Cambridge Healthtech Institute’s 11th Annual World Pharma Congress, […]

Ben Franklin Technology Partners Invests $110,000 in QR Pharma

Berwyn, PA, April 3, 2012 QR Pharma, Inc.(QR), a clinical-stage specialty pharmaceutical company committed to developing novel approaches for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders, announced today the receipt of a $110,000 investment from Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP). This funding is in addition to […]

QR Pharma Awarded Funding by Michael J. Fox Foundation to Test Posiphen® as a Treatment for Parkinson’s Disease

Berwyn, PA, March 6, 2012 QR Pharma, Inc.(QR), a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer’s disease,Parkinson’s disease (PD) and other neurodegenerative disorders, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the company $468,000 to conduct research for the development […]